The mineralocorticoid receptor and its coregulators
The mineralocorticoid receptor (MR) is a member of the nuclear receptor superfamily and is essential for controlling sodium transport in epithelial tissues such as the kidney and colon. Moreover, it is also present in other non-epithelial tissues and is capable of activation by both mineralocorticoids and glucocorticoids. A challenge in understanding transcriptional regulation by the MR and other nuclear receptors is to determine how tissue- and ligand-specificity is achieved. Over the past decade, it has become clear that a heterogeneous group of non-receptor proteins termed as coregulators are required to either enhance or repress nuclear receptor-mediated transactivation of target genes. A subset of these coregulators may be expected to confer specificity to MR-mediated responses by virtue of their variable tissue expression and selectivity for different ligands. Specific coregulator-MR interactions may be a suitable target in the rational design of tissue-specific MR modulators as has been described for other steroid receptors. However, the number of coregulators identified to date for the MR is very limited compared with other nuclear receptors. Understanding the full complement of MR coregulators is essential for unraveling the complexity of MR signaling pathways and will facilitate the development of selective MR modulators.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2009 |
---|---|
Erschienen: |
2009 |
Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
---|---|
Enthalten in: |
Journal of molecular endocrinology - 43(2009), 2 vom: 25. Aug., Seite 53-64 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Yang, Jun [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 03.09.2009 Date Revised 19.11.2009 published: Print Citation Status MEDLINE |
---|
doi: |
10.1677/JME-09-0031 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM190096527 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM190096527 | ||
003 | DE-627 | ||
005 | 20231223184749.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231223s2009 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1677/JME-09-0031 |2 doi | |
028 | 5 | 2 | |a pubmed24n0634.xml |
035 | |a (DE-627)NLM190096527 | ||
035 | |a (NLM)19617444 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Yang, Jun |e verfasserin |4 aut | |
245 | 1 | 4 | |a The mineralocorticoid receptor and its coregulators |
264 | 1 | |c 2009 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 03.09.2009 | ||
500 | |a Date Revised 19.11.2009 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The mineralocorticoid receptor (MR) is a member of the nuclear receptor superfamily and is essential for controlling sodium transport in epithelial tissues such as the kidney and colon. Moreover, it is also present in other non-epithelial tissues and is capable of activation by both mineralocorticoids and glucocorticoids. A challenge in understanding transcriptional regulation by the MR and other nuclear receptors is to determine how tissue- and ligand-specificity is achieved. Over the past decade, it has become clear that a heterogeneous group of non-receptor proteins termed as coregulators are required to either enhance or repress nuclear receptor-mediated transactivation of target genes. A subset of these coregulators may be expected to confer specificity to MR-mediated responses by virtue of their variable tissue expression and selectivity for different ligands. Specific coregulator-MR interactions may be a suitable target in the rational design of tissue-specific MR modulators as has been described for other steroid receptors. However, the number of coregulators identified to date for the MR is very limited compared with other nuclear receptors. Understanding the full complement of MR coregulators is essential for unraveling the complexity of MR signaling pathways and will facilitate the development of selective MR modulators | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Review | |
650 | 7 | |a DNA-Binding Proteins |2 NLM | |
650 | 7 | |a NCOR2 protein, human |2 NLM | |
650 | 7 | |a Nuclear Receptor Co-Repressor 2 |2 NLM | |
650 | 7 | |a PPAR gamma |2 NLM | |
650 | 7 | |a Receptors, Mineralocorticoid |2 NLM | |
650 | 7 | |a Repressor Proteins |2 NLM | |
650 | 7 | |a Transcription Factors |2 NLM | |
650 | 7 | |a Histone Acetyltransferases |2 NLM | |
650 | 7 | |a EC 2.3.1.48 |2 NLM | |
650 | 7 | |a NCOA1 protein, human |2 NLM | |
650 | 7 | |a EC 2.3.1.48 |2 NLM | |
650 | 7 | |a Nuclear Receptor Coactivator 1 |2 NLM | |
650 | 7 | |a EC 2.3.1.48 |2 NLM | |
700 | 1 | |a Young, Morag J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of molecular endocrinology |d 1996 |g 43(2009), 2 vom: 25. Aug., Seite 53-64 |w (DE-627)NLM012626864 |x 1479-6813 |7 nnns |
773 | 1 | 8 | |g volume:43 |g year:2009 |g number:2 |g day:25 |g month:08 |g pages:53-64 |
856 | 4 | 0 | |u http://dx.doi.org/10.1677/JME-09-0031 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 43 |j 2009 |e 2 |b 25 |c 08 |h 53-64 |